The Use of Porcine Acellular Dermal Matrix in Single-stage, Implant-based Immediate Breast Reconstruction: A 2-center Retrospective Outcome Study by Loo, YL & Haider, S
 www.PRSGlobalOpen.com 1
Copyright © 2018 The Authors. Published by Wolters Kluwer Health, 
Inc. on behalf of The American Society of Plastic Surgeons. This 
is an open access article distributed under the Creative Commons 
Attribution License 4.0 (CCBY), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original 
work is properly cited.
INTRODUCTION TO STRATTICE
First introduced in 2001, acellular dermal matrix 
(ADM) has become increasingly popular in primary tis-
sue expander or implant-based breast reconstruction 
over the past decade.1–3 As many as 87% of breast sur-
geons globally have used ADMs in implant-based breast 
reconstructions. The use of ADM in immediate breast 
reconstructions is as high as 56%.3,4 Plastic surgeons have 
begun to use it in secondary and cosmetic breast recon-
structions aiming for better cosmetic outcomes and high-
er patient satisfaction rate.5–8
There have been many reported benefits of the usage 
of ADMs in breast reconstruction. ADM reduces the need 
for rectus abdominis muscle and serratus anterior coverage 
by providing an inferolateral coverage of the implant/tissue 
expander. Risk of implant exposure has also been greatly re-
duced with more satisfying definition of the inframammary 
and lateral mammary folds.9,10 In addition, the risk of capsu-
lar contracture is lower compared with non-ADM cohorts.10,11
A variety of studies have been published on human 
ADM breast reconstruction outcomes and techniques; 
however, UK legislation prohibits the use of human tis-
sue.12,13 Due to this, tissue expander/implant-based breast 
reconstructions mainly use porcine materials such as Strat-
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tice. A study14 found no difference in the outcome of hu-
man and nonhuman ADMs; however, the cohort was small 
and follow-up period was limited. We designed this study 
to formally evaluate the long-term outcome of Strattice 
use in a large cohort of breast reconstructions in Greater 
Manchester and Royal Free London Hospital (RFH) to 
share our experience with the use of Strattice.
METHODS
A retrospective review was performed of case notes of 
all patients who underwent implant-based breast recon-
struction using Strattice at University Hospital of South 
Manchester (UHSM) and Greater Manchester and RFH, 
United Kingdom. All implant-based reconstructions were 
performed by breast and plastic surgeons at UHSM and 
RFH. Two breast surgeons and 4 plastic surgeons were in-
volved at UHSM, and 1 breast surgeon and 3 plastic sur-
geons were involved at RFH. In most cases, mastectomies 
were performed by breast surgeons and immediate breast 
reconstruction by a plastic surgeon in a joined case. How-
ever, there was an oncoplastic breast surgeon at UHSM 
who performed both procedures. Patients who underwent 
immediate implant-based breast reconstruction using 
Strattice between March 2009 and November 2017 were 
included in the study.
Data Extraction
Patients’ data were collected using a standardized study 
proforma, which included age, comorbidities such as smok-
ing and obesity (body mass index, >30), indication for mas-
tectomy, adjuvant therapies, length of drain in situ, implant 
size, and presence of complications. Complications includ-
ed major and minor infections, implant loss, skin necrosis, 
hematoma, implant exposure, and seromas. Incidences of 
capsular contracture were not extracted because incidence 
of capsular contracture was not assessed in this study. Cel-
lulitis was classified under infections. Major infections were 
defined as infections that resulted in implant loss, whereas 
minor infections were classified as infections resolved with 
antibiotics treatment without further interventions. Patients’ 
smoking status was based on whether they were smoking at 
the time of follow-up. Indications for mastectomy include 
prophylactic BRCA (Breast Cancer susceptibility gene) gene 
carrier, family history, contralateral risk-reducing procedure, 
oncologic indications, contralateral cosmetic procedure, re-
vision, and delayed breast reconstruction.
Patient selection was nonrandomized and uncon-
trolled. Patient suitability for single-stage, implant-based 
breast reconstruction using Strattice was assessed by the 
operating surgeons and also based on patient’s prefer-
ence. Exclusion criteria were patients who had 2-staged re-
construction and patients who were younger than 18 years 
old. Patients were followed up by consultant and registrar 
grade surgeons in clinic.
Statistical Analysis
Statistical comparisons of complications in inva-
sive and risk-reducing mastectomy were performed 
and comparisons between our Strattice data. Statistical 
comparisons between the 2 cohorts were done using in-
dependent t test on SPSS. A P value of less than 0.05 
was considered to be statistically significant. Regression 
analysis was performed using SPSS to include the effect 
of all confounding factors on the outcome associated 
with the use of Strattice.
Surgical Technique
The surgical technique of immediate breast reconstruc-
tion using ADM, Strattice, has been previously described 
in many articles.2,7,10,14,15 All breast cancer patients were dis-
cussed in MDT (Multi-disciplinary Team meeting). All pa-
tients were given intravenous antibiotics during induction 
of general anesthesia. Skin incision was usually performed 
through a nipple removing skin-sparing or inframammary 
approach. The pectoralis major muscle was then lifted over 
the underlying chest wall to create a subpectoral pocket for 
the implant. The inferolateral edge of the pectoralis major 
muscle was lifted without excessive detachment of the ster-
nal origin of the pectoralis muscle because it may result 
in medial migration of the implant. The porcine ADM, 
Strattice, was then soaked in sterile saline for a minimum 
of 2 washes before using it. The ADM usually measures 
8 × 16 cm and shaped before covering the implant at the in-
ferior border of the pectoralis major muscle. Based on the 
surgeon and patient’s preference, either a round- or tear-
drop-shaped silicone implant was placed into subpectoral 
pocket and the inferior border of the pectoralis muscle was 
sutured to the superior border of the Strattice. The infe-
rior border of the matrix was then sutured at the inframa-
mmary and lateral mammary fold using 2.0 polydioxanone 
(PDS (Ethicon, Somerville, New Jersey)). The incisions 
were then closed according to the anatomical layers after 2 
drains were inserted into the subcutaneous space and deep 
to the implant in each breast. The Strattice ADM was not 
palpable in most cases. Drainage was monitored postopera-
tively. Patients were continued on intravenous antibiotics 
(Augmentin or Co-amoxiclav) up to 48 hours postopera-
tively followed by oral antibiotics upon discharge.
RESULTS
A total of 400 direct-to-implant breast reconstructions 
were performed on 320 patients at UHSM and 450 breast 
reconstructions on 350 patients at RFH. Patients between 
24 and 75 years old (median, 50 years) who underwent 
prophylactic, oncologic, revision, and delayed recon-
structions were all included in this study. Of 320 UHSM 
patients, 250 patients (62.5%) were unilateral and 75 
(37.5%) were bilateral breast reconstruction. Sixty-three 
percent were indicated for invasive breast cancer, 22.5% 
were risk-reducing procedures, 7.5% were revision sur-
geries, and only 1% were delayed breast reconstructions 
(Table 1). Hundred patients (31.12%) had adjuvant che-
motherapy, 70 patients (21.9%) had neoadjuvant chemo-
therapy, and a total of 60 patients (18.75%) previously 
had radiotherapy. Mean follow-up period was 28.9 months 
(range, 1–60 months). The mean implant volume for 
single-stage breast reconstructions was 444.5 mL (range, 
150–600 mL).
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In the Royal Free London (RFH) cohort, 276 patients 
(61.3%) had unilateral mastectomy and 87 patients (38.7%) 
had bilateral mastectomy (Table 2). Patients (64.4%) were 
indicated for invasive procedure, 24.89% were risk reduc-
ing, 8.89% were revision surgeries, and 1.78% were de-
layed breast reconstructions. One hundred fifteen patients 
(32.9%) had adjuvant chemotherapy, 80 patients (22.9%) 
had neoadjuvant chemotherapy, and a total of 71 patients 
(20.3%) previously had radiotherapy. Both cohorts were 
direct-to-implant breast reconstruction using only Strattice 
ADM. Mean follow-up period was 32.5 months (range, 1–70 
months). The mean implant volume for the breast recon-
structions was 434.6 mL (range, 160–700 mL).
The overall complication rate for UHSM cohort was 
28% (112 breasts). Forty-five breasts (11.25%) had se-
roma, 20 breasts (5%) had major infections, 25 breasts 
(6.25%) had minor infections, 22 breasts (5.5%) had skin 
necrosis, 15 breasts (15%) had hematomas, 8 breasts (2%) 
had implant loss, and 5 breasts (1.25%) had implant ex-
posure. The complication rates were further stratified into 
groups based on indication for surgery. One-way analysis 
of variance found that there were no significant differenc-
es between the outcomes of each group (Table 3).
The overall complication rate for RFH cohort was 
37.8% (170 breasts). Sixty breasts (13.33%) had seroma, 30 
breasts (6.67%) had minor infections, 24 breasts (5.33%) 
had major infections, 20 breasts (4.44%) had skin necro-
sis, 18 breasts (4%) had hematoma, and 8 breasts (1.78%) 
had implant exposure. One-way analysis of variance did 
not find any significant difference between outcomes of 
different surgical indication groups (Table 4).
In both centers, all patients had seromas aspirated 
without any other significant complications. Most of the 
complications were observed postoperatively and 4 weeks 
postsurgery at the outpatient clinic. In these patients, 
there was no evidence of seroma at the time of 6-month 
follow-up. According to case notes, most patients were dis-
charged at a mean of 3 days (range, 1–14 days). The drains 
were removed between 6 and 23 days after surgery. In the 
UHSM cohort, we observed that 15 patients had major or 
minor infections and 8 patients had skin necrosis during 
the course of chemotherapy when compared with 25 pa-
tients and 14 patients who had major or minor infections 
and skin necrosis, respectively, in the RFH cohort. With re-
gard to radiotherapy, we found that 5 UHSM patients and 
8 RFH patients had skin necrosis after having postopera-
tive radiotherapy. There were no patients lost to follow-up.
Using the independent t test, we compared the complica-
tions individually between the 2 large cohorts (UHSM versus 
RFH) and found that there were no statistically significant dif-
ferences in outcomes between the groups (Table 5). Regres-
sion analysis was done as shown in Tables 6 and 7 to include 
all confounding factors individually and their effects on the 
outcome of Strattice in both cohorts. In the UHSM cohort, ra-
diotherapy had a significant impact on the rate of minor infec-
tions and skin necrosis at P = 0.030 and P = 0.041, respectively 
(Table 6). Regression analysis of the RFH cohort revealed statis-
tically significant effects of smoking on seroma rate at P = 0.045 
and skin necrosis rate at P = 0.037. Adjuvant chemotherapy had 
a significant impact on minor infection rate at P = 0.041 and 
radiotherapy on minor infection and skin necrosis rate at P = 
0.029 and P = 0.032, respectively (Table 7), in RFH cohort.
DISCUSSION
The use of ADM allows for single-stage breast recon-
struction. Although the cost of ADM may be more expen-
sive, fewer clinic visits and revision surgeries are thought 
to contribute to lesser financial burden.12
We observed a total complication rate of 28% and 37.8% 
with Strattice-assisted breast reconstruction in the UHSM 
and RFH cohort, respectively. This complication rate was 
approximately similar compared to a comprehensive lit-
erature review done by Krishnan et al16 that revealed an 
average complication rate of 30% in breast reconstruction 
using ADMs. A review of reports on non-ADM breast recon-
struction shows an average complication rate of 34.5%.16–19
In a separate report, Castelló et al19 reported a high 
complication rate of 37% in a series of 56 immediate 
breast reconstructions with anatomic integrated-valve ex-
panders. In contrast to round and Becker expanders that 
have uniform and softer surface, anatomic expanders 
have inflation port with a rigid ring on the superoanterior 
Table 1. Patient Demographics, Comorbidities, Adjuvant 





Unilateral mastectomy, n (% breasts) 250(62.5)
Bilateral mastectomy, n (% breasts) 75 (37.5)
Comorbidity, n (% patients)  
  Smoking 100 (31.25)
  Obesity 55 (17.19)
Neoadjuvant chemotherapy, n (% patients) 70 (21.9)
Adjuvant therapy, n (% patients)  
  Chemotherapy 100 (31.25)
  Radiotherapy 60 (18.75)
Indications, n (% breasts)  
  Invasive 252 (63)
  Risk reducing 90 (22.5)
  Revision 30 (7.5)
  Delayed 4 (1)
Table 2. Patient Demographics, Comorbidities, Adjuvant 





Unilateral mastectomy, n (% breasts) 276 (61.3)
Bilateral mastectomy, n (% breasts) 87 (38.7)
Comorbidity, n (% patients)  
  Smoking 125 (35.7)
  Obesity 73 (20.86)
Neoadjuvant chemotherapy, n (% patients) 80 (22.9)
Adjuvant therapy, n (% patients)  
  Chemotherapy 115 (32.86)
  Radiotherapy 71 (20.29)
Indications, n (% breasts)  
  Invasive 290 (64.4)
  Risk reducing 112 (24.89)
  Revision 40 (8.89)
  Delayed 8 (1.77)
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surface, embedded in the body. This rigid ring presses on 
the mastectomy flap as it inflates. Thus, the higher com-
plication rate may be due to the design of the port.19 This 
can potentially be risky in patients undergoing immediate 
single-stage reconstruction and in irradiated patients.20
According to a pooled analysis of the complications of 
ADMs in breast reconstructions mainly Alloderm (Life-
Cell Corp., Branchburg, N.J.),21 infection rates were 5.7% 
and 2% for cellulitis. However, in our study, analysis for in-
fection and cellulitis was performed together. Our major 
and minor infection rate 5% and 6.25%, respectively, in 
UHSM cohort and 5.33% and 6.67% in RFH cohort were 
comparable to the 7.7% infection rate from the meta-anal-
ysis in ADM. Another meta-analysis done by Newman et 
al22 reported an infection rate of 5.6% in implant-based 
breast reconstruction using ADMs. However, they did not 
clearly define the term ‘‘infection,” that is, whether it in-
cluded cellulitis or differentiate between infections that 










Total complication, n (% of 400 breasts) 112 (28) 80 (20) 27 (6.75) 5 (1.25) 0.075
  Major infection 20 (5) 18 (4.5) 1 (0.25) 1 (0.25) 0.126
  Minor infection 25 (6.25) 20 (5) 3 (0.75) 2 (0.5) 0.055
  Implant loss and explantation 8 (2) 5 (1.25) 3 (0.75) 1 (0.25) 0.089
  Skin necrosis 22 (5.5) 16 (4) 4 (1) 2 (0.5) 0.105
  Hematoma 15 (3.75) 6 (1.5) 5 (1.25) 4 (1) 0.057
  Implant exposure 5 (1.25) 3 (0.75) 1 (0.25) 1 (0.25) 0.077
  Seroma 45(11.25) 25 (6.25) 12 (3) 8 (2) 0.059
ANOVA, analysis of variance.











Total complication, n (% of 450 breasts) 170 (37.8) 110 (24.44) 55 (12.22) 5 (1.11) 0.085
  Major infection 24 (5.33) 20 (4.44) 3 (0.67) 1 (0.22) 0.050
  Minor infection 30 (6.67) 24 (5.33) 4 (0.89) 2 (0.44) 0.051
  Implant loss and explantation 10 (2.22) 7 (1.56) 2 (0.44) 1 (0.22) 0.076
  Skin necrosis 20 (4.44) 14 (3.1) 4 (0.89) 2 (0.44) 0.059
  Hematoma 18 (4) 10 (2.22) 5 (1.11) 3 (0.67) 0.066
  Implant exposure 8 (1.78) 5 (1.11) 2 (0.44) 1 (0.22) 0.079
  Seroma 60(13.33) 40 (8.89) 12 (2.67) 8 (1.78) 0.054
ANOVA, analysis of variance.
Table 5. Complications in UHSM Cohort Versus RFH Cohorts P Value <0.05 Indicates Statistical Significance
 
UHSM Strattice Cohort, 
N = 400 Breasts
RFH Strattice Cohort, 
N = 450 Breasts
Independent t  
Test (P)
Total complication, n 112 170 0.067
  Major infection 20 24 0.055
  Minor infection 25 30 0.079
  Implant loss and explantation 8 10 0.088
  Skin necrosis 22 20 0.102
  Hematoma 15 18 0.098
  Implant exposure 5 8 0.211
  Seroma 45 60 0.223
Table 6. Regression Analysis of Outcome and Confounding Effects on Strattice in UHSM Cohort Using SPSS






Predictors: (Constant),  
Neoadjuvant Chemotherapy




Major infection 0.059 0.132 0.886 0.973 0.077
Minor Infection 0.066 0.177 0.291 0.071 0.030*
Seroma 0.076 0.082 0.086 0.223 0.092
Hematoma 0.205 0.575 0.165 0.921 0.366
Implant loss 0.085 0.098 0.576 0.665 0.422
Implant exposure 0.066 0.445 0.643 0.331 0.778
Skin necrosis 0.055 0.519 0.534 0.901 0.041*
*P < 0.05 = statistically significant.
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were minor (requiring medical management) or major 
(requiring surgical intervention). A baseline infection 
rate of 2%–35%21,23 in implant-based breast reconstruc-
tion without ADM was observed.
Quality of the skin flap intraoperatively was recorded 
in the operative notes to be in good and acceptable quality 
having good capillary refill time, color, turgor, and tempera-
ture before reconstruction. Yanko et al20 reported a skin flap 
necrosis rate of 18.2% in total of 170 breast reconstruction 
using anatomic, Becker, and round expanders compared 
with 4.44% and 5.5% skin flap necrosis rate in UHSM and 
RFH cohort, respectively. The total complication rate re-
ported was very high at 70.6% (120 breasts). Although their 
study was based on 3 types of tissue expanders, the number 
of breasts with complication was significantly higher in the 
2-stage tissue expander–based reconstruction. Spear and 
Majidian24 reported a skin flap necrosis rate of 8.0% in their 
experience with tissue expanders in a series of a 171 breasts 
reconstruction, whereas Salzberg et al11 in his study of 466 
breast reconstruction with Alloderm reported a low skin ne-
crosis rate of 1.1% (5 breasts), which is significantly lower 
when compared with our data.
Our study reported a postoperative hematoma rate of 
3.75% and 4% in UHSM and RFH cohort, respectively. A 
study in 2012 by Salzberg et al8 reported a hematoma rate 
of 1.9% in 105 breast reconstructions with Strattice. A study 
by Cordeiro and McCarthy25 found a hematoma rate of only 
0.44% in 2,276 2-stage tissue expander breast reconstructions.
Although our RFH cohort did report significant impact of 
radiotherapy on incidence of minor infection and skin necro-
sis, there have not been many articles concluding radiother-
apy as a risk of complications such as capsular contracture, 
infection, and implant failure.26 Furthermore, Gunnarsson 
et al27 reported that chemotherapy and radiotherapy did not 
increase complication rates in Strattice patients, whereas our 
study showed that adjuvant chemotherapy did increase the 
risk of minor infection. In our study, most of these patients 
were found to still be actively smoking at the time of follow-
up. Gunnarsson et al27 reported smoking as a factor for fail-
ure, which is similarly reflected in Table 7. Although we did 
not assess the incidence of capsular contracture in our study, 
several studies with a mean follow-up of 6.5–52 months have 
reported low capsular contracture rate with regard to the use 
of ADM in immediate breast reconstruction.28,29,31
A cost analysis study by Jansen and Macadam28,29,31 
 reported that human ADMs are much more cost-effective 
when compared with the 2-stage breast reconstruction. The 
significant cost incurred by the cost of Strattice itself is com-
pensated by the overall reconstruction with fewer revisions 
and better esthetic outcome.3 Because our retrospective 
cohort study only looked at immediate single-stage breast 
reconstruction cases, we did not compare the cost-effective-
ness with 2-stage expander/implant reconstructions.
One of the main limitations of our study was that there 
were no records of costs associated with the use of Strat-
tice that were documented at the time of data collection, 
which made it very difficult for us to perform a cost analy-
sis to further improve our study. Because this was a ret-
rospective cohort study, patient selection was not blinded 
but selected based on patient’s preference or clinician’s 
advice, therefore, susceptible to selection bias.
Both of our cohort from Manchester and London re-
ported comparable complication rates when compared 
with reports on human ADMs and tissue expander–based 
breast reconstructions. Despite having data collected from 
2 different large units in the United Kingdom, our reports 
showed promising and acceptable results. There is still a 
need for future studies to compare the cost-effectiveness of 
single-stage immediate breast reconstruction using Strat-
tice and 2-stage tissue expander–based reconstruction.
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